Overview Dividends

(DVA) DaVita HealthCare Partners - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US23918K1088

Dialysis Services, Laboratory Testing, Integrated Care

Health Care Services
Market Cap in USD: 8,330m

IPO / Inception: 1995-10-31
Return 12m vs S&P 500: -36.7%

EPS (Earnings per Share)

EPS CAGR: 5.96%
EPS Trend: 50.7%

Last SUE: -2.85
Qual. Beats: 0

Revenue

Rev. CAGR: 4.08%
Rev. Trend: 93.9%

Last SUE: -0.33
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	31.1%
Value at Risk 5%th	46.5%
Relative Tail Risk	-9.19%

Reward TTM
Sharpe Ratio	-0.93
Alpha	-35.63
CAGR/Max DD	0.43

Character TTM
Hurst Exponent	0.372
Beta	0.485
Beta Downside	0.218

Drawdowns 3y
Max DD	35.49%
Mean DD	10.88%
Median DD	6.60%

Description: DVA DaVita HealthCare Partners October 30, 2025

DaVita Inc. (NYSE:DVA) is the United States’ largest provider of kidney dialysis services, operating a network of outpatient dialysis centers that deliver in-center, hospital-based, and home-based hemodialysis, along with related laboratory and administrative support. The firm also offers integrated care programs, disease-management services, clinical research, physician services, and a niche transplant-software business. The company, originally incorporated as DaVita HealthCare Partners in 1994, rebranded to DaVita Inc. in September 2016 and is headquartered in Denver, Colorado.

Key operating metrics as of FY 2023 include approximately 2,900 dialysis centers serving over 200,000 patients, generating $12.5 billion in revenue-about 90 % of which is derived from Medicare fee-for-service reimbursements. Growth is being driven by three sector trends: (1) an aging U.S. population that is expanding the end-stage renal disease (ESRD) prevalence pool (≈750 k patients), (2) a policy shift encouraging home-based dialysis, which DaVita is positioning to capture through its “DaVita Home” platform, and (3) ongoing Medicare payment reforms that reward value-based care and outcomes, pressuring providers to improve efficiency and patient outcomes.

For a deeper, data-rich analysis of DaVita’s valuation dynamics and how these macro-drivers may affect its future cash flows, you may find the free research tools on ValueRay worth exploring.

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (771.9m TTM) > 0 and > 6% of Revenue (6% = 799.1m TTM)

FCFTA 0.07 (>2.0%) and ΔFCFTA -0.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 8.22% (prev 8.63%; Δ -0.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.11 (>3.0%) and CFO 1.89b > Net Income 771.9m (YES >=105%, WARN >=100%)

Net Debt (14.17b) to EBITDA (2.65b) ratio: 5.35 <= 3.0 (WARN <= 3.5)

Current Ratio 1.36 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (73.8m) change vs 12m ago -14.02% (target <= -2.0% for YES)

Gross Margin 31.98% (prev 32.80%; Δ -0.83pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 75.57% (prev 72.37%; Δ 3.20pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 3.42 (EBITDA TTM 2.65b / Interest Expense TTM 570.4m) >= 6 (WARN >= 3)

Altman Z'' 1.65

(A) 0.06 = (Total Current Assets 4.11b - Total Current Liabilities 3.02b) / Total Assets 17.74b

(B) 0.12 = Retained Earnings (Balance) 2.05b / Total Assets 17.74b

(D) 0.12 = Book Value of Equity 1.93b / Total Liabilities 16.22b

Total Rating: 1.65 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 69.37

1. Piotroski 4.50pt

2. FCF Yield 5.74%

3. FCF Margin 9.70%

4. Debt/Equity -26.02

5. Debt/Ebitda 5.35

6. ROIC - WACC (= 12.40)%

7. RoE -283.9%

8. Rev. Trend 93.88%

9. EPS Trend 50.66%

What is the price of DVA shares?

As of December 26, 2025, the stock is trading at USD 114.41 with a total of 329,000 shares traded.
Over the past week, the price has changed by -1.50%, over one month by -5.73%, over three months by -12.17% and over the past year by -26.44%.

Is DVA a buy, sell or hold?

DaVita HealthCare Partners has received a consensus analysts rating of 3.10. Therefor, it is recommend to hold DVA.

Strong Buy: 1
Buy: 0
Hold: 8
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the DVA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	144.5	26.3%
Analysts Target Price	144.5	26.3%
ValueRay Target Price	107.6	-6%

DVA Fundamental Data Overview December 24, 2025

Market Cap USD = 8.33b (8.33b USD * 1.0 USD.USD)
P/E Trailing = 12.0237
P/E Forward = 9.1324
P/S = 0.6255
P/B = 21.6266
P/EG = 1.1007
Beta = 0.994
Revenue TTM = 13.32b USD
EBIT TTM = 1.95b USD
EBITDA TTM = 2.65b USD
Long Term Debt = 10.18b USD (from longTermDebt, last quarter)
Short Term Debt = 494.9m USD (from shortTermDebt, last quarter)
Debt = 14.88b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.17b USD (from netDebt column, last quarter)
Enterprise Value = 22.50b USD (8.33b + Debt 14.88b - CCE 706.0m)
Interest Coverage Ratio = 3.42 (Ebit TTM 1.95b / Interest Expense TTM 570.4m)
FCF Yield = 5.74% (FCF TTM 1.29b / Enterprise Value 22.50b)
FCF Margin = 9.70% (FCF TTM 1.29b / Revenue TTM 13.32b)
Net Margin = 5.80% (Net Income TTM 771.9m / Revenue TTM 13.32b)
Gross Margin = 31.98% ((Revenue TTM 13.32b - Cost of Revenue TTM 9.06b) / Revenue TTM)
Gross Margin QoQ = 31.80% (prev 33.08%)
Tobins Q-Ratio = 1.27 (Enterprise Value 22.50b / Total Assets 17.74b)
Interest Expense / Debt = 1.01% (Interest Expense 150.6m / Debt 14.88b)
Taxrate = 22.20% (68.6m / 308.8m)
NOPAT = 1.52b (EBIT 1.95b * (1 - 22.20%))
Current Ratio = 1.36 (Total Current Assets 4.11b / Total Current Liabilities 3.02b)
Debt / Equity = -26.02 (negative equity) (Debt 14.88b / totalStockholderEquity, last quarter -571.9m)
Debt / EBITDA = 5.35 (Net Debt 14.17b / EBITDA 2.65b)
Debt / FCF = 10.97 (Net Debt 14.17b / FCF TTM 1.29b)
Total Stockholder Equity = -271.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.35% (Net Income 771.9m / Total Assets 17.74b)
RoE = -283.9% (negative equity) (Net Income TTM 771.9m / Total Stockholder Equity -271.9m)
RoCE = 19.65% (EBIT 1.95b / Capital Employed (Equity -271.9m + L.T.Debt 10.18b))
RoIC = 15.70% (NOPAT 1.52b / Invested Capital 9.65b)
WACC = 3.30% (E(8.33b)/V(23.21b) * Re(7.80%) + D(14.88b)/V(23.21b) * Rd(1.01%) * (1-Tc(0.22)))
Discount Rate = 7.80% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -10.83%
[DCF Debug] Terminal Value 78.34% ; FCFE base≈1.34b ; Y1≈1.35b ; Y5≈1.44b
Fair Price DCF = 360.4 (DCF Value 25.45b / Shares Outstanding 70.6m; 5y FCF grow -0.16% → 3.0% )
EPS Correlation: 50.66 | EPS CAGR: 5.96% | SUE: -2.85 | # QB: 0
Revenue Correlation: 93.88 | Revenue CAGR: 4.08% | SUE: -0.33 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.46 | Chg30d=+0.096 | Revisions Net=+3 | Analysts=3
EPS next Year (2026-12-31): EPS=12.74 | Chg30d=+0.103 | Revisions Net=-1 | Growth EPS=+19.3% | Growth Revenue=+3.3%

Additional Sources for DVA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle